Meng Y, Liu X, Ma K, et al. Association of *MTHFR* C677T polymorphism and type 2 diabetes mellitus (T2DM) susceptibility. Mol Genet Genomic Med. 2019;7:e1020 10.1002/mgg3.1020

1. INTRODUCTION {#mgg31020-sec-0005}
===============

Type 2 diabetes mellitus (T2DM) is a major public health problem that not only affects individual life quality, but also increases social economic burden (DeFronzo et al., [2015](#mgg31020-bib-0014){ref-type="ref"}). The frequency of T2DM in China is increasing quickly, with estimation of about 380 million T2DM patients by 2025 (van Dieren, Beulens, van der Schouw, Grobbee, & Neal, [2010](#mgg31020-bib-0061){ref-type="ref"}). The etiology of T2DM remains partly elucidated. Evidences suggest that T2DM is a complex disease caused by the combinations of environmental and genetic risk factors (Wareham, Franks, & Harding, [2002](#mgg31020-bib-0067){ref-type="ref"}; Zeggini et al., [2007](#mgg31020-bib-0077){ref-type="ref"}).

Previous reports showed that individuals with insufficient intake of folic acid were more likely to have T2DM. Folate is a methyl group donor in the synthesis of intracellular methylation reactions and de novo deoxynucleoside (Blount et al., [1997](#mgg31020-bib-0006){ref-type="ref"}). When folate deficiency, the DNA stability will be impaired (Duthie, [1999](#mgg31020-bib-0015){ref-type="ref"}). Methylenetetrahydrofolate reductase (MTHFR) is a folate‐metabolizing enzyme that participates in folic acid circulation and DNA synthesis (Friso et al., [2002](#mgg31020-bib-0020){ref-type="ref"}). MTHFR catalyzes the irreversible reduction of 5,10‐methylenetetrahydrofolate to 5‐methyltetrahydrofolate (Niclot et al., [2006](#mgg31020-bib-0039){ref-type="ref"}). Dysfunction or low activity of MTHFR may decrease the level of methyl pool; consequently, it inhibits the successful deoxynucleoside synthesis and intracellular methylation reactions (Rozen, [1997](#mgg31020-bib-0047){ref-type="ref"}).

The human gene *MTHFR* (OMIM number: 607093) is located on chromosome 1p36.3. Of all the identified SNPs, C677T (Ala222Val, rs1801133 C\>T) is one of the most investigated genetic variations (Adinolfi et al., [2005](#mgg31020-bib-0001){ref-type="ref"}; Liew & Gupta, [2015](#mgg31020-bib-0029){ref-type="ref"}). The C677T polymorphism is a C to T transition at base pair 677, which results in the amino acid transition from Ala to Val. Such amino acid transition significantly decreases the activity of MTHFR (Weisberg, Tran, Christensen, Sibani, & Rozen, [1998](#mgg31020-bib-0068){ref-type="ref"}). Recent data suggested that there exist an association between C677T and the susceptibility of T2DM. However, the role of C667T in risk of T2DM was discrepant. Several meta‐analyses that were conducted to solve this conflicting role somehow failed. To get a precise estimation, we re‐analyzed the role of *MTHFR* C677T on T2DM via including larger eligible investigations.

2. MATERIALS AND METHODS {#mgg31020-sec-0006}
========================

2.1. Literature search {#mgg31020-sec-0007}
----------------------

We carried out a comprehensive literature search in the following databases: PubMed, EMBASE, CNKI, and Wanfang. The searching was updated to October 2019 without any language limitations. The combination of the following search terms was adopted: '*MTHFR* or methylenetetrahydrofolate reductase', and 'polymorphism or polymorphisms or SNP or single nucleotide polymorphism or variant' and 'diabetes or mellitus or diabetes mellitus or T2DM'. To expand the included studies, we also retrieved eligible references from the selected studies. The GenBank reference sequence and version number for the gene is: *MTHFR* (NM_005957.5).

2.2. Inclusion/exclusion criteria {#mgg31020-sec-0008}
---------------------------------

We set the following criteria when performing the selection work: (a) evaluating the association of *MTHFR* C677T polymorphism with T2DM risk; (b) case--control design; (c) odds ratios (ORs) and their 95% confidence intervals (CIs) were able to obtain; and (d) reports Hardy--Weinberg equilibrium (HWE). Exclusion criteria were as follows: (a) reviews or meta‐analyses; (b) case‐only studies or case reports; and (c) duplicate publications.

2.3. Data extraction {#mgg31020-sec-0009}
--------------------

We arranged three authors to handle data extraction: two authors to extract data independently and one author to resolve the disagreement. The following data were selectively extracted from each study: first author\'s surname, year of publication, country, ethnicity, genotyping methods, and genotypic distribution. The stratification analysis was conducted by ethnicity (Asians, Caucasians, and Africans) and HWE (HWE \<0.05 and HWE \>0.05).

2.4. Statistical methods {#mgg31020-sec-0010}
------------------------

STATA 11.0 software (Stata Corporation) was adopted to conduct the current meta‐analysis. We first used Chi‐square test to check whether the genotype frequency of C677T among the controls was in HWE. After that, we determined the relationship between *MTHFR* C677T polymorphism and T2DM risk by calculating pooled ORs with the corresponding 95% CIs. We totally used five genetic models: homozygote model (TT vs. CC), heterozygote model (CT vs. CC), recessive model (TT vs. CT/CC), dominant model (CT/TT vs. CC), and allele model (T vs. C) to detect such relationship. Stratification analyses were also taken by ethnicity (Asian, Caucasian, and African) and HWE (HWE \<0.05 and HWE \>0.05), aiming to detect the source of heterogeneity. We carried out Chi‐square‐based Q statistic test and inconsistency index statistics (*I* ^2^) to calculate heterogeneity between study results. If the studies were homogeneous (with *p^het^* \< .10 or *I* ^2^ \> 50%), the random‐effects model (the DerSimonian and Laird method) was chosen. Otherwise, ORs were calculated using the fixed‐effects model (the Mantel‐Haenszel method). Sensitivity analysis was performed to assess the strength of the conclusion, by sequentially excluding each study at a time. Begg\'s funnel plot and Egger\'s linear regression test were conducted to assess publication bias. We also conducted quality assessment to detect the quality of each study using the quality assessment criteria (He et al., [2014](#mgg31020-bib-0024){ref-type="ref"}). All the statistics were two‐sided. *p* \< .05 was considered as significant.

3. RESULTS {#mgg31020-sec-0011}
==========

3.1. Study search {#mgg31020-sec-0012}
-----------------

General process of publication selection was graphically shown in Figure [1](#mgg31020-fig-0001){ref-type="fig"}. Initial retrieval from PubMed and EMBASE databases got a total of 78 and 45 potentially relevant published records, respectively. We also obtained 18 articles from Chinese databases CNKI and Wanfang. After titles and abstracts screening, 81 nonrelevant records were excluded. The remaining 60 articles and eight additional articles identified from retrieved studies were included in the final meta‐analysis (Al‐Harbi et al., [2015](#mgg31020-bib-0002){ref-type="ref"}; Al‐Salihi, Ajeena, Al‐Kashwan, & Al‐Lebban, [2016](#mgg31020-bib-0004){ref-type="ref"}; Zidan, El Mougy, Moustafa, El attar, & Mohamed, [2019](#mgg31020-bib-0085){ref-type="ref"}; Benrahma et al., [2012](#mgg31020-bib-0005){ref-type="ref"}; Bluthner et al., [1999](#mgg31020-bib-0007){ref-type="ref"}; Cao, Huang, Mao, & Gao, [2005](#mgg31020-bib-0008){ref-type="ref"}; Chang et al., [2011](#mgg31020-bib-0009){ref-type="ref"}; Chen, Ning, Zhu, Li, & Shi, [2004](#mgg31020-bib-0010){ref-type="ref"}; Chen et al., [2010](#mgg31020-bib-0011){ref-type="ref"}; P. Chen, Pan, Sun, Bai, & Fu, [2008](#mgg31020-bib-0012){ref-type="ref"}; Dai & Yu, [2012](#mgg31020-bib-0013){ref-type="ref"}; El Hajj Chehadeh et al., [2016](#mgg31020-bib-0016){ref-type="ref"}; Eroglu et al., [2007](#mgg31020-bib-0017){ref-type="ref"}; Errera et al., [2006](#mgg31020-bib-0018){ref-type="ref"}; Fekih‐Mrissa et al., [2017](#mgg31020-bib-0019){ref-type="ref"}; Fujita et al., [1999](#mgg31020-bib-0021){ref-type="ref"}; Guo, Pan, Chu, Guo, & Sun, [2005](#mgg31020-bib-0022){ref-type="ref"}; Guo et al., [2002](#mgg31020-bib-0023){ref-type="ref"}; Hu, Zhang, Fang, Qin, & Liu, [2009](#mgg31020-bib-0025){ref-type="ref"}; Hu, Gan, Li, & Bi, [2001](#mgg31020-bib-0026){ref-type="ref"}; Jimenez‐Ramirez et al., [2017](#mgg31020-bib-0027){ref-type="ref"}; Ksiazek, Bednarek‐Skublewska, & Buraczynska, [2004](#mgg31020-bib-0028){ref-type="ref"}; Lin, Wang, & Liu, [2009](#mgg31020-bib-0030){ref-type="ref"}; Liu et al., [2014](#mgg31020-bib-0031){ref-type="ref"}; Luo, Yan, Li, Cheng, & Song, [2007](#mgg31020-bib-0032){ref-type="ref"}; Luo, Yan, Ma, Cheng, & Song, [2008](#mgg31020-bib-0033){ref-type="ref"}; Mao, Gao, Qin, & Shi, [2004](#mgg31020-bib-0034){ref-type="ref"}; Mehri et al., [2010](#mgg31020-bib-0035){ref-type="ref"}; Mei, Chen, & Zheng, [2012](#mgg31020-bib-0036){ref-type="ref"}; Mtiraoui et al., [2007](#mgg31020-bib-0037){ref-type="ref"}; Neugebauer, Baba, & Watanabe, [1998](#mgg31020-bib-0038){ref-type="ref"}; Nithya et al., [2017](#mgg31020-bib-0040){ref-type="ref"}; Odawara & Yamashita, [1999](#mgg31020-bib-0041){ref-type="ref"}; Pirozzi et al., [2018](#mgg31020-bib-0042){ref-type="ref"}; Qiu, [2009](#mgg31020-bib-0043){ref-type="ref"}; Rahimi et al., [2009](#mgg31020-bib-0044){ref-type="ref"}; Ramanathan, Harichandana, Kannan, Elumalai, & Sfd, [2019](#mgg31020-bib-0045){ref-type="ref"}; Raza, Abbas, Siddiqi, & Mahdi, [2017](#mgg31020-bib-0046){ref-type="ref"}; Settin, El‐Baz, Ismaeel, Tolba, & Allah, [2015](#mgg31020-bib-0048){ref-type="ref"}; Shang, Wang, & Liu, [2017](#mgg31020-bib-0049){ref-type="ref"}; Shi, He, Cheng, Wang, & Liu, [2006](#mgg31020-bib-0050){ref-type="ref"}; J. Shi, Li, Yu, Chen, & Tao, [2002](#mgg31020-bib-0051){ref-type="ref"}; Shpichinetsky et al., [2000](#mgg31020-bib-0052){ref-type="ref"}; Soares et al., [2008](#mgg31020-bib-0053){ref-type="ref"}; J. Sun, Xu, Xue, Zhu, & Lu, [2005](#mgg31020-bib-0055){ref-type="ref"}; Sun, Xu, & Zhu, [2001](#mgg31020-bib-0056){ref-type="ref"}; Sun, Xu, Zhu, & Lu, [2004](#mgg31020-bib-0057){ref-type="ref"}; Sun, Xu, Lu, & Zhu, [2009](#mgg31020-bib-0054){ref-type="ref"}; Sun, Chen, et al., [2004](#mgg31020-bib-0058){ref-type="ref"}; Sun, Wang, Shi, & Yang, [2013](#mgg31020-bib-0059){ref-type="ref"}; Wang et al., [2017](#mgg31020-bib-0062){ref-type="ref"}; Wang, Hu, Xiao, & Wan, [2014](#mgg31020-bib-0063){ref-type="ref"}; Wang, Wang, & Li, [2018](#mgg31020-bib-0064){ref-type="ref"}; Wang, Wang, Xue, Chen, & Zou, [2001](#mgg31020-bib-0065){ref-type="ref"}; Wang, Wang, Xue, Cheng, et al., [2001](#mgg31020-bib-0066){ref-type="ref"}; Wen, Lu, Li, Wu, & Zhang, [2008](#mgg31020-bib-0069){ref-type="ref"}; Wirta et al., [1998](#mgg31020-bib-0070){ref-type="ref"}; Xiao, Hu, Shan, Guan, & Ren, [2006](#mgg31020-bib-0071){ref-type="ref"}; Xu, Zhang, Shan, & Ma, [2003](#mgg31020-bib-0072){ref-type="ref"}; Yang, Lu, & Pan, [2001](#mgg31020-bib-0073){ref-type="ref"}; Yilmaz, Agachan, Ergen, Karaalib, & Isbir, [2004](#mgg31020-bib-0074){ref-type="ref"}; Yoshioka et al., [2004](#mgg31020-bib-0075){ref-type="ref"}; Yue, Liu, Kang, Hu, & Qiu, [2006](#mgg31020-bib-0076){ref-type="ref"}; Zhang, Li, Liu, & Hu, [2007](#mgg31020-bib-0078){ref-type="ref"}; Zhang, Xiang, Weng, & Li, [2002](#mgg31020-bib-0079){ref-type="ref"}; Zhang & Liu, [2009](#mgg31020-bib-0080){ref-type="ref"}; Zhi et al., [2016](#mgg31020-bib-0081){ref-type="ref"}; Zhou, Li, & Zhang, [2004](#mgg31020-bib-0083){ref-type="ref"}).

![Search flow diagram](MGG3-7-e1020-g001){#mgg31020-fig-0001}

3.2. Study characteristics {#mgg31020-sec-0013}
--------------------------

The study characteristics of the final selected studies were presented in Table [1](#mgg31020-tbl-0001){ref-type="table"}. A total of 68 studies with 10,812 cases and 8,745 controls were included in our final meta‐analysis. Among these eligible studies, 52 were done on Asians, 11 studies were done on Caucasians, and five studies were done on Africans. As to the HWE, genotype distribution in the controls of 52 studies was agreed with the HWE, and 16 studies were not. We also classified the studies into low‐quality studies (48 studies) and high‐quality studies (20 studies) by quality score.

###### 

Characteristics of studies included in the current meta‐analysis

  Surname               Year   Country                Ethnicity   Genotype method   Case   Control   HWE   Score                                     
  --------------------- ------ ---------------------- ----------- ----------------- ------ --------- ----- ------- ----- ----- ----- ----- --------- ----
  Neugebauer            1998   Japan                  Asian       PCR‐RFLP          24     31        12    67      86    43    17    146   0.003     6
  Wirta V               1998   Finland                Caucasian   PCR‐RFLP          46     30        8     84      60    48    7     115   0.520     8
  Bluthner              1999   Germany/Poland         Caucasian   PCR‐RFLP          74     50        23    147     67    68    15    150   0.708     6
  Fujita                1999   Japan                  Asian       PCR‐RFLP          31     57        17    105     20    39    9     68    0.142     7
  Odawara               1999   Japan                  Asian       PCR‐RFLP          52     65        26    143     38    68    25    131   0.578     7
  Shpichinetsky         2000   Israel                 Caucasian   PCR‐RFLP          23     22        10    55      21    16    6     43    0.316     3
  Hu S                  2001   China                  Asian       PCR‐RFLP          49     48        16    113     30    24    1     55    0.121     5
  Sun J                 2001   China                  Asian       PCR‐RFLP          32     33        20    85      10    16    31    57    0.008     4
  Wang L                2001   China                  Asian       PCR‐RFLP          52     68        41    161     37    36    12    85    0.502     5
  Wang L                2001   China                  Asian       PCR‐RFLP          65     75        39    179     37    38    10    85    0.959     7
  Yang G                2001   China                  Asian       PCR‐RFLP          17     27        23    67      26    28    8     62    0.914     6
  Guo Q                 2002   China                  Asian       PCR‐RFLP          12     19        22    53      12    11    5     28    0.391     7
  Shi J                 2002   China                  Asian       PCR‐RFLP          12     31        7     50      22    29    5     56    0.291     5
  Zhang G               2002   China                  Asian       PCR‐RFLP          56     108       34    198     40    49    11    100   0.484     7
  Xu J                  2003   China                  Asian       PCR‐RFLP          39     54        30    123     20    25    7     52    0.853     8
  Chen A                2004   China                  Asian       PCR‐RFLP          24     45        22    91      21    9     5     35    0.038     7
  Ksiazek P             2004   Poland                 Caucasian   PCR‐RFLP          159    123       44    326     71    83    16    170   0.237     10
  Mao L                 2004   China                  Asian       PCR‐RFLP          35     37        11    83      26    18    3     47    0.960     8
  Sun J                 2004   China                  Asian       PCR‐RFLP          102    76        42    220     74    34    22    130   \<0.001   9
  Sun L                 2004   China                  Asian       PCR‐RFLP          27     52        27    106     29    18    3     50    0.925     7
  Yilmaz H              2004   Turkey                 Caucasian   PCR‐RFLP          121    98        30    249     101   93    20    214   0.831     8
  Yoshioka K            2004   Japan                  Asian       PCR‐RFLP          21     13        6     40      71    107   29    207   0.260     9
  Zhou J                2004   China                  Asian       PCR‐RFLP          16     78        45    139     8     31    30    69    0.998     8
  Cao H                 2005   China                  Asian       PCR‐RFLP          14     20        6     40      26    18    3     47    0.960     7
  Guo L                 2005   China                  Asian       PCR‐RFLP          60     51        50    161     58    34    35    127   \<0.001   8
  Sun J                 2005   China                  Asian       PCR‐RFLP          101    78        49    228     63    31    20    114   \<0.001   10
  Errera FI             2006   Brazil                 Caucasian   PCR‐RFLP          44     41        10    95      36    57    14    107   0.244     9
  Shi C                 2006   China                  Asian       PCR‐RFLP          108    60        18    186     68    34    7     109   0.338     8
  Xiao Y                2006   China                  Asian       PCR‐RFLP          16     53        4     73      47    25    1     73    0.245     7
  Yue H                 2006   China                  Asian       PCR‐RFLP          66     131       55    252     17    11    2     30    0.903     8
  Eroglu Z              2007   Turkey                 Caucasian   PCR‐RFLP          51     45        7     103     63    58    7     128   0.171     7
  Luo D                 2007   China                  Asian       PCR‐RFLP          65     102       26    193     42    35    14    91    0.151     7
  Mtiraoui N            2007   Tunisia                Caucasian   PCR‐RFLP          163    135       62    360     270   94    36    400   \<0.001   12
  Zhang C               2007   China                  Asian       PCR‐RFLP          28     29        19    76      34    19    12    65    0.006     8
  Chen P                2008   China                  Asian       PCR‐RFLP          19     70        27    116     14    73    37    124   0.014     9
  Luo D                 2008   China                  Asian       PCR‐RFLP          59     63        19    141     43    31    11    85    0.166     8
  Soares AL             2008   Brazil                 Caucasian   PCR‐RFLP          15     8         2     25      9     5     2     16    0.363     3
  Wen J                 2008   China                  Asian       PCR‐RFLP          22     50        23    95      27    25    5     57    0.816     6
  Hu L                  2009   China                  Asian       PCR‐RFLP          47     63        49    159     26    17    9     52    0.053     7
  Lin R                 2009   China                  Asian       PCR‐RFLP          56     36        47    139     93    22    24    139   \<0.001   10
  Qiu Y                 2009   China                  Asian       PCR‐RFLP          83     68        48    199     53    29    18    100   \<0.001   9
  Rahimi Z              2009   Iran                   Asian       PCR‐RFLP          33     27        5     65      33    22    4     59    0.898     5
  Sun J                 2009   China                  Asian       PCR‐RFLP          94     73        48    215     78    38    26    142   \<0.001   10
  Zhang Q               2009   China                  Asian       PCR‐RFLP          66     94        66    226     26    17    9     52    0.053     8
  Chen A                2010   China                  Asian       PCR‐RFLP          57     74        27    158     34    17    4     55    0.373     8
  Mehri S               2010   Tunisia                African     PCR‐RFLP          50     49        16    115     66    38    12    116   0.078     8
  Chang YH              2011   China                  Asian       PCR               1      25        30    56      3     23    36    62    0.781     6
  Houda Benrahma        2012   Morocco                African     PCR‐RFLP          160    97        25    282     114   122   26    262   0.420     10
  Dai H                 2012   China                  Asian       PCR‐RFLP          51     54        15    120     31    27    2     60    0.176     8
  Mei Q                 2012   China                  Asian       PCR‐RFLP          17     51        23    91      17    70    37    124   0.076     8
  Sun L                 2013   China                  Asian       PCR‐RFLP          180    243       48    471     30    42    6     78    0.094     11
  Liu K                 2014   China                  Asian       PCR‐RFLP          103    54        6     163     54    23    0     77    0.123     8
  Han Wang              2014   China                  Asian       TaqMan            234    293       66    593     298   312   70    680   0.377     12
  Al‐Harbi EM           2015   Bahrain                Asian       PCR‐RFLP          116    43        12    171     135   47    6     188   0.449     10
  Ahmad Settin          2015   Egypt                  African     PCR‐RFLP          111    65        27    203     156   135   20    311   0.195     11
  Al‐Salihi NJ          2016   Iraqi                  Asian       PCR‐RFLP          28     28        5     61      12    10    0     22    0.167     4
  El Hajj Chehadeh SW   2016   United Arab Emirates   Asian       TaqMan            155    49        5     209     132   27    10    169   \<0.001   10
  Xueyuan Zhi           2016   China                  Asian       TaqMan            28     86        66    180     76    172   102   350   0.826     11
  Fekih‐Mrissa N        2017   Tunisia                African     PCR‐RFLP          56     102       2     160     124   68    8     200   0.726     11
  Jimenez‐Ramirez FJ    2017   Puerto Rico            Caucasian   PCR‐RFLP          72     8         9     89      184   159   57    400   0.020     10
  K Nithya              2017   India                  Asian       PCR‐RFLP          173    25        2     200     94    6     0     100   0.757     10
  Raza ST               2017   India                  Asian       PCR‐RFLP          152    162       65    379     102   52    26    180   \<0.001   11
  Shang G               2017   China                  Asian       PCR‐RFLP          84     106       36    226     66    91    37    194   0.573     11
  Wang D                2017   China                  Asian       PCR‐RFLP          69     72        21    162     162   127   13    302   0.052     10
  Pirozzi FF            2018   Brazil                 Caucasian   PCR‐RFLP          17     22        8     47      30    38    9     77    0.560     7
  Wang J                2018   China                  Asian       PCR‐RFLP          176    101       103   380     183   70    53    306   \<0.001   11
  Ramanathan G          2019   India                  Asian       PCR‐RFLP          72     71        2     145     81    19    0     100   0.293     10
  Zidan                 2019   Egypt                  African     PCR‐RFLP          30     51        39    120     54    6     0     60    0.683     9

Abbreviations: HWE, Hardy--Weinberg equilibrium; PCR‐RFLP, polymerase chain reaction‐restriction fragment length polymorphism.
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3.3. Meta‐analysis results {#mgg31020-sec-0014}
--------------------------

Table [2](#mgg31020-tbl-0002){ref-type="table"} and Figure [2](#mgg31020-fig-0002){ref-type="fig"} illustrated the main results of the current meta‐analysis. We adopted five genetic models to assess the association between *MTHFR* C677T and T2DM: homozygote model TT versus CC, heterozygous model CT versus CC, recessive model TT versus CT/CC, dominant model CT/TT versus CC, and allele model T versus C. There was a significant association between *MTHFR* C677T polymorphism and T2DM under homozygous (OR = 1.64, 95% CI = 1.39--1.94), heterozygous (OR = 1.38, 95% CI = 1.20--1.59), recessive (OR = 1.41, 95% CI = 1.23--1.61), dominant (OR = 1.47, 95% CI = 1.27--1.70), and allele (OR = 1.37, 95% CI = 1.23--1.52) genetic models in a random‐effects model.

###### 

Meta‐analysis of the association between *MTHFR* C677T polymorphism and T2DM susceptibility

  Variables       No. of studies   Homozygous              Heterozygous   Recessive               Dominant   Allele                                                                                     
  --------------- ---------------- ----------------------- -------------- ----------------------- ---------- ----------------------- --------- ----------------------- -------- ----------------------- --------
  All             68               **1.64 (1.39--1.94)**   \<.001         **1.38 (1.20--1.59)**   \<.001     **1.41 (1.23--1.61)**   \<0.001   **1.47 (1.27--1.70)**   \<.001   **1.37 (1.23--1.52)**   \<.001
  Ethnicity                                                                                                                                                                                             
  Asian           52               **1.78 (1.48--2.15)**   \<.001         **1.51 (1.33--1.70)**   \<.001     **1.43 (1.23--1.67)**   \<0.001   **1.60 (1.40--1.82)**   \<.001   **1.44 (1.29--1.59)**   \<.001
  Caucasian       11               1.20 (0.81--1.79)       .007           0.79 (0.52--1.21)       \<.001     **1.43 (1.14--1.79)**   0.457     0.87 (0.57--1.32)       \<.001   0.97 (0.72--1.32)       \<.001
  African         5                1.70 (0.63--4.57)       \<.001         1.88(0.75--4.74)        \<.001     1.45 (0.62--3.39)       0.002     2.15 (0.86--5.42)       \<.001   1.92 (0.98--3.73)       \<.001
  HWE                                                                                                                                                                                                   
  \>0.05          52               **1.76 (1.45--2.13)**   \<.001         **1.34 (1.14--1.57)**   \<.001     **1.50 (1.29--1.75)**   0.006     **1.48 (1.26--1.73)**   \<.001   **1.39 (1.24--1.56)**   \<.001
  ≤0.05           16               1.38 (0.99--1.92)       \<.001         **1.48 (1.11--1.99)**   \<.001     1.19 (0.92--1.55)       \<0.001   **1.44 (1.07--1.95)**   \<.001   **1.29 (1.01--1.65)**   \<.001
  Quality score                                                                                                                                                                                         
  \>9             20               **1.46 (1.12--1.89)**   \<.001         1.29 (0.99--1.69)       \<.001     **1.37 (1.12--1.68)**   0.003     **1.36 (1.05--1.75)**   \<.001   **1.30 (1.09--1.56)**   \<.001
  ≤9              48               **1.78 (1.43--2.23)**   \<.001         **1.42 (1.21--1.67)**   \<.001     **1.45 (1.21--1.73)**   0.001     **1.53 (1.29--1.82)**   \<.001   **1.40 (1.23--1.60)**   \<.001

The GenBank reference sequence and version number for the gene is: *MTHFR* (NM_005957.5). Values were in bold if 95% CIs excluded 1 or *p* values less than .05.

Abbreviations: CI, confidence interval; Het, heterogeneity; HWE, Hardy--Weinberg equilibrium; OR, odds ratio; T2DM, type 2 diabetes mellitus.
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![Forest plot of association between *MTHFR* C677T polymorphism and T2DM under homozygous model. The horizontal lines represent the study‐specific ORs and 95% CIs, respectively. The diamond represents the pooled results of OR and 95% CI. CI, confidence interval; OR, odds ratio; T2DM, type 2 diabetes mellitus](MGG3-7-e1020-g002){#mgg31020-fig-0002}

In the subgroup analysis based on ethnicity, we divided the included studies into three ethnicities: Asian, Caucasian, and African. We found significant association between *MTHFR* C677T genotype and T2DM in Asian populations, under each genetic models homozygous (OR = 1.78, 95% CI = 1.48--2.15), heterozygous (OR = 1.51, 95% CI = 1.33--1.70), recessive (OR = 1.43, 95% CI = 1.23--1.67), dominant (OR = 1.60, 95% CI = 1.40--1.82), and allele (OR = 1.44, 95% CI = 1.29--1.59). However, no relationship was found between *MTHFR* C677T genotype and T2DM in Caucasian and African, except for the recessive model in Caucasian group (OR = 1.43, 95% CI = 1.14--1.79). When stratified by HWE, significant association was also observed in the subgroup of HWE \>0.05, under homozygous (OR = 1.76, 95% CI = 1.45--2.13), heterozygous (OR = 1.34, 95% CI = 1.14--1.57), recessive (OR = 1.50, 95% CI = 1.29--1.75), dominant (OR = 1.48, 95% CI = 1.26--1.73), and allele (OR = 1.39, 95% CI = 1.24--1.56) genetic models. Significant association was detected in heterozygous (OR = 1.48, 95% CI = 1.11--1.99), dominant (OR = 1.44, 95% CI = 1.07--1.95), and allele (OR = 1.29, 95% CI = 1.01--1.65) in the subgroup of HWE \< 0.05. A subgroup analysis stratified by quality score was also conducted. Significant association was detected in homozygous (OR = 1.46, 95% CI = 1.12--1.89), recessive (OR = 1.37, 95% CI = 1.12--1.68), dominant (OR = 1.36, 95% CI = 1.05--1.75), and allele (OR = 1.30, 95% CI = 1.09--1.56) genetic models, in the subgroup of quality score \> 9. Significant association was also detected in homozygous (OR = 1.78, 95% CI = 1.43--2.23), heterozygous (OR = 1.42, 95% CI = 1.21--1.67), recessive (OR = 1.45, 95% CI = 1.21--1.73), dominant (OR = 1.53, 95% CI = 1.29--1.82), and allele (OR = 1.40, 95% CI = 1.23--1.60) genetic models, in the subgroup of quality score ≤9.

3.4. Heterogeneity and sensitivity analysis {#mgg31020-sec-0015}
-------------------------------------------

As shown in Table [1](#mgg31020-tbl-0001){ref-type="table"}, substantial heterogeneities could be found among all the genetic models (*p* \< .001) for the *MTHFR* C677T. Therefore, the random‐effect model was used to calculate the pooled ORs and 95% CIs for all the models.

Sensitivity analysis using sequential leave‐one‐out strategy was carried out to explore the influence of a single study on the pooled ORs. The omission of each study did not impact the recalculated ORs, indicating the credibility and reliability of our results (Figure [3](#mgg31020-fig-0003){ref-type="fig"}).

![Sensitivity analysis of the association between *MTHFR* C677T polymorphism and T2DM. Each point represents the recalculated OR after deleting a separate study. OR, odds ratio; T2DM, type 2 diabetes mellitus](MGG3-7-e1020-g003){#mgg31020-fig-0003}

3.5. Publication bias {#mgg31020-sec-0016}
---------------------

Begg\'s funnel plot and quantitative Egger\'s test were adopted to test the publication bias of the current meta‐analysis. As indicated by the symmetrical shape of the Begg\'s funnel plots, no significant publication bias was observed (Figure [4](#mgg31020-fig-0004){ref-type="fig"}). Moreover, Egger\'s test also suggested the nonexistence of publication bias among the studies (data not shown).

![Funnel plot analysis for assessing publication bias for *MTHFR* C677T polymorphism under homozygous model. Each point represents a separate study for the indicated association](MGG3-7-e1020-g004){#mgg31020-fig-0004}

4. DISCUSSION {#mgg31020-sec-0017}
=============

To our knowledge, the current meta‐analysis represents the largest and most comprehensive one regarding the relationship between *MTHFR* C677T and T2DM so far. Our analysis provided strong evidence that *MTHFR* C677T was significantly associated with T2DM, especially in Asians. Sensitivity analysis indicated that there was no significant change in the overall results by removing one study in each turn. Publication bias analysis also showed that the results are convincible.

*MTHFR* C677T is a functional genetic variation that leads to amino acid substitution from alanine to valine (Ueland, Hustad, Schneede, Refsum, & Vollset, [2001](#mgg31020-bib-0060){ref-type="ref"}). Such amino acid shift was illustrated to compromise the enzyme activity to nearly 50%, compared to the wild‐type MTHFR enzyme (Weisberg et al., [1998](#mgg31020-bib-0068){ref-type="ref"}). Although the relationship between T2DM susceptibility and *MTHFR* C677T genotype has been largely investigated, contradictory conclusions still remain. In 2006, no evidence of association was found by F.I.V. Errera et al. between the 677TT genotype of *MTHFR* and T2DM, in Brazilian populations (Errera et al., [2006](#mgg31020-bib-0018){ref-type="ref"}). In a study conducted in China in 2014, Wang et al. found that C677T in the *MTHFR* may influence the risk of T2DM (Wang et al., [2014](#mgg31020-bib-0063){ref-type="ref"}). Recently, in a case--control study conducted in the population of Brazilian with 47 T2DM cases and 78 controls by Flavio Fontes Pirozzi et al. (Pirozzi et al., [2018](#mgg31020-bib-0042){ref-type="ref"}), no correlation was found between the *MTHFR* C677T in the development of T2DM.

Due to the divergent results among single‐country studies, several systematic meta‐analyses have been undertaken to determine conclusively whether *MTHFR* C677T is associated with the risk of T2DM. In 2013, Chinese academics Zhong, Rodriguez, Yang, and Li ([2013](#mgg31020-bib-0082){ref-type="ref"}) conducted a meta‐analysis regarding *MTHFR* C677T and T2DM. Their meta‐analysis included 4,855 T2DM patients and 5,242 controls. However, they failed to obtain clear evidence of a significant association of *MTHFR* C677T and T2DM across all 39 studies conducted in 15 countries. They also failed to provide compelling evidence of an association specifically for African, Asian, or Caucasian populations. Interestingly, Khalid et al. (Al‐Rubeaan et al., [2013](#mgg31020-bib-0003){ref-type="ref"}) observed that there was a significant relationship between *MTHFR* C677T polymorphism and T2DM in Arab population, in 2013. In 2014, Zhu et al. ([2014](#mgg31020-bib-0084){ref-type="ref"}) conducted an updated meta‐analysis in Chinese population aiming to better identify the role of C677T polymorphism in T2DM. They included 29 studies with 4,656 T2DM patients and 2,127 controls. They detected a significant relationship between *MTHFR* C677T polymorphism and T2DM in the Chinese Han population.

Genotype frequencies at the C677T locus of *MTHFR* vary widely by ethnicity (Errera et al., [2006](#mgg31020-bib-0018){ref-type="ref"}; Yilmaz et al., [2004](#mgg31020-bib-0074){ref-type="ref"}), raising the possibility that any association between this SNP and the risk of T2DM may likewise depend on ethnicity. Thus, we further put our focus on ethnic stratification analysis based on the groups that emerged from our literature searches: African, Asian, and Caucasian. Our analysis provided strong evidence that *MTHFR* C677T was significantly associated with T2DM in Asians, but not in Caucasians or Africans. Thus, it is necessary to identify the role of C677T in different ethnicities.

Several weaknesses should be pointed out before interpreting our conclusion. First, selection bias could not be avoided as only the articles in English and Chinese were analyzed. Other studies written in other languages were unable to include. Second, analyzing one SNP in *MTHFR* was far more enough, as the development of T2DM was associated with multiple SNPs in multiple genes. Third, we also failed to determine the role of other potential influential factors in the initiation of T2DM. These potential influential factors such as life style, environment exposures, and gene--environment interactions were reported to be associated with T2DM. Fourth, it is inevitable to avoid several shortages such as misclassified genotypes, unwell‐matched sources of controls, and inconsistent qualities of the included studies, due to the retrospective nature of meta‐analysis. Finally, between‐study heterogeneity was found in all comparisons, which may compromise the reliability of conclusion.

5. CONCLUSION {#mgg31020-sec-0018}
=============

In all, this meta‐analysis provides a precise conclusion that *MTHFR* C677T polymorphism was significantly associated with T2DM, especially in Asian populations. Further well‐designed, large‐scale, and in‐depth studies are warranted to check such relationship.
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